Octagon Therapeutics, a preclinical-stage biopharmaceutical company developing targeted medicines for autoimmune disease, has initiated a research collaboration with Novo Nordisk focused on inflammatory disease. This multi-year relationship will apply Octagon’s functional target discovery approach and novel chemistry strategy in disease areas in which Novo Nordisk has specific expertise.   Octagon’s lead program selectively targets a population of pathologically activated B cells t...